Per Munck af Rosenschold

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5262128/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Positron Emission Tomography Based Elucidation of the Enhanced Permeability and Retention Effect in Dogs with Cancer Using Copper-64 Liposomes. ACS Nano, 2015, 9, 6985-6995.	7.3	220
2	Deviations in delineated GTV caused by artefacts in 4DCT. Radiotherapy and Oncology, 2010, 96, 61-66.	0.3	136
3	Radiobiological risk estimates of adverse events and secondary cancer for proton and photon radiation therapy of pediatric medulloblastoma. Acta Oncológica, 2011, 50, 806-816.	0.8	132
4	Impact of Dose to the Bladder Trigone on Long-Term Urinary Function After High-Dose Intensity Modulated Radiation Therapy for Localized Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2014, 88, 339-344.	0.4	122
5	Estimated risk of cardiovascular disease and secondary cancers with modern highly conformal radiotherapy for early-stage mediastinal Hodgkin lymphoma. Annals of Oncology, 2013, 24, 2113-2118.	0.6	121
6	Boron neutron capture therapy for glioblastoma multiforme: clinical studies in Sweden. Journal of Neuro-Oncology, 2003, 62, 135-144.	1.4	116
7	Patient QA systems for rotational radiation therapy: A comparative experimental study with intentional errors. Medical Physics, 2013, 40, 031716.	1.6	98
8	Improvement in toxicity in high risk prostate cancer patients treated with image-guided intensity-modulated radiotherapy compared to 3D conformal radiotherapy without daily image guidance. Radiation Oncology, 2014, 9, 44.	1.2	93
9	Risk of Developing Cardiovascular Disease After InvolvedÂNode Radiotherapy Versus Mantle Field for Hodgkin Lymphoma. International Journal of Radiation Oncology Biology Physics, 2012, 83, 1232-1237.	0.4	91
10	A dosimetric comparison of real-time adaptive and non-adaptive radiotherapy: A multi-institutional study encompassing robotic, gimbaled, multileaf collimator and couch tracking. Radiotherapy and Oncology, 2016, 119, 159-165.	0.3	82
11	Three-dimensional MRI-linac intra-fraction guidance using multiple orthogonal cine-MRI planes. Physics in Medicine and Biology, 2013, 58, 4943-4950.	1.6	81
12	Estimated clinical benefit of protecting neurogenesis in the developing brain during radiation therapy for pediatric medulloblastoma. Neuro-Oncology, 2012, 14, 882-889.	0.6	69
13	Real-time dynamic MLC tracking for inversely optimized arc radiotherapy. Radiotherapy and Oncology, 2010, 94, 218-223.	0.3	62
14	ESTRO ACROP consensus guideline on the use of image guided radiation therapy for localized prostate cancer. Radiotherapy and Oncology, 2019, 141, 5-13.	0.3	62
15	Life years lost—comparing potentially fatal late complications after radiotherapy for pediatric medulloblastoma on a common scale. Cancer, 2012, 118, 5432-5440.	2.0	61
16	Impact of [18F]-fluoro-ethyl-tyrosine PET imaging on target definition for radiation therapy of high-grade glioma. Neuro-Oncology, 2015, 17, 757-763.	0.6	58
17	The prognostic value of FET PET at radiotherapy planning in newly diagnosed glioblastoma. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 373-381.	3.3	54
18	Artifacts in Conventional Computed Tomography (CT) and Free Breathing Four-Dimensional CT Induce Uncertainty in Gross Tumor Volume Determination. International Journal of Radiation Oncology Biology Physics, 2011, 80, 1573-1580.	0.4	53

#	Article	IF	CITATIONS
19	AAPM Task Group 264: The safe clinical implementation of MLC tracking in radiotherapy. Medical Physics, 2021, 48, e44-e64.	1.6	49
20	Boron Neutron Capture Therapy for Glioblastoma Multiforme: Clinical Studies in Sweden. Journal of Neuro-Oncology, 2003, 62, 135-144.	1.4	47
21	Establishment and Initial Experience of Clinical FLASH Radiotherapy in Canine Cancer Patients. Frontiers in Oncology, 2021, 11, 658004.	1.3	45
22	Feasibility of multi-parametric PET and MRI for prediction of tumour recurrence in patients with glioblastoma. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 603-613.	3.3	44
23	Photon and proton therapy planning comparison for malignant glioma based on CT, FDG-PET, DTI-MRI and fiber tracking. Acta Oncológica, 2011, 50, 777-783.	0.8	38
24	Patterns and Predictors of Amelioration of Genitourinary Toxicity After High-dose Intensity-modulated Radiation Therapy for Localized Prostate Cancer: Implications for Defining Postradiotherapy Urinary Toxicity. European Urology, 2013, 64, 931-938.	0.9	38
25	Hippocampal sparing radiotherapy for pediatric medulloblastoma: impact of treatment margins and treatment technique. Neuro-Oncology, 2014, 16, 594-602.	0.6	36
26	A treatment planning and delivery comparison of volumetric modulated arc therapy with or without flattening filter for gliomas, brain metastases, prostate, head/neck and early stage lung cancer. Acta Oncológica, 2014, 53, 1005-1011.	0.8	35
27	Robustness of the Voluntary Breath-Hold Approach for the Treatment of Peripheral Lung Tumors Using Hypofractionated Pencil Beam Scanning Proton Therapy. International Journal of Radiation Oncology Biology Physics, 2016, 95, 534-541.	0.4	35
28	Interobserver delineation variation in lung tumour stereotactic body radiotherapy. British Journal of Radiology, 2012, 85, e654-e660.	1.0	33
29	Target position uncertainty during visually guided deep-inspiration breath-hold radiotherapy in locally advanced lung cancer. Radiotherapy and Oncology, 2017, 123, 78-84.	0.3	33
30	Prognostic value of 18F-FET PET imaging in re-irradiation of high-grade glioma: Results of a phase I clinical trial. Radiotherapy and Oncology, 2016, 121, 132-137.	0.3	31
31	A modality-adaptive method for segmenting brain tumors and organs-at-risk in radiation therapy planning. Medical Image Analysis, 2019, 54, 220-237.	7.0	31
32	Toward clinical application of prompt gamma spectroscopy forin vivomonitoring of boron uptake in boron neutron capture therapy. Medical Physics, 2001, 28, 787-795.	1.6	30
33	Patterns of failure for patients with glioblastoma following O-(2-[18 F]fluoroethyl)- L -tyrosine PET- and MRI-guided radiotherapy. Radiotherapy and Oncology, 2017, 122, 380-386.	0.3	30
34	Feasibility of Pencil Beam Scanned Intensity Modulated Proton Therapy in Breath-hold for Locally Advanced Non-Small Cell Lung Cancer. International Journal of Radiation Oncology Biology Physics, 2017, 99, 1121-1128.	0.4	30
35	Monte Carlo calculations of thermal neutron capture in gadolinium: A comparison of GEANT4 and MCNP with measurements. Medical Physics, 2006, 33, 337-341.	1.6	29
36	Injectable Colloidal Gold for Use in Intrafractional 2D Imageâ€Guided Radiation Therapy. Advanced Healthcare Materials, 2015, 4, 856-863.	3.9	29

#	Article	IF	CITATIONS
37	Liquid fiducial marker performance during radiotherapy of locally advanced non small cell lung cancer. Radiotherapy and Oncology, 2016, 121, 64-69.	0.3	29
38	Early Postoperative 18F-FET PET/MRI for Pediatric Brain and Spinal Cord Tumors. Journal of Nuclear Medicine, 2019, 60, 1053-1058.	2.8	29
39	Quantification and comparison of visibility and image artifacts of a new liquid fiducial marker in a lung phantom for image-guided radiation therapy. Medical Physics, 2015, 42, 2818-2826.	1.6	28
40	Doses to Carotid Arteries After Modern Radiation Therapy for Hodgkin Lymphoma: Is Stroke Still a Late Effect of Treatment?. International Journal of Radiation Oncology Biology Physics, 2013, 87, 297-303.	0.4	27
41	The effect on esophagus after different radiotherapy techniques for early stage Hodgkin's lymphoma. Acta Oncológica, 2013, 52, 1559-1565.	0.8	27
42	An international dosimetry exchange for boron neutron capture therapy, Part I: Absorbed dose measurements. Medical Physics, 2005, 32, 3729-3736.	1.6	26
43	Visual outcome after fractionated stereotactic radiation therapy of benign anterior skull base tumors. Journal of Neuro-Oncology, 2014, 118, 101-108.	1.4	26
44	Brain Tumor Segmentation Using a Generative Model with an RBM Prior on Tumor Shape. Lecture Notes in Computer Science, 2016, , 168-180.	1.0	25
45	Kilovoltage x-ray dosimetry—an experimental comparison between different dosimetry protocols. Physics in Medicine and Biology, 2008, 53, 4431-4442.	1.6	22
46	Visual outcome, endocrine function and tumor control after fractionated stereotactic radiation therapy of craniopharyngiomas in adults: findings in a prospective cohort. Acta Oncológica, 2017, 56, 415-421.	0.8	22
47	Liquid fiducial marker applicability in proton therapy of locally advanced lung cancer. Radiotherapy and Oncology, 2017, 122, 393-399.	0.3	22
48	Dosimetry for gadolinium neutron capture therapy (GdNCT). Radiation Measurements, 2013, 59, 233-240.	0.7	21
49	Toxicity and efficacy of re-irradiation of high-grade glioma in a phase I dose- and volume escalation trial. Radiotherapy and Oncology, 2017, 125, 223-227.	0.3	21
50	Stability of percutaneously implanted markers for lung stereotactic radiotherapy. Journal of Applied Clinical Medical Physics, 2013, 14, 187-195.	0.8	20
51	A Retrospective Evaluation of the Benefit of Referring Pediatric Cancer Patients to an External Proton Therapy Center. Pediatric Blood and Cancer, 2016, 63, 262-269.	0.8	19
52	Monte Carlo model of the Studsvik BNCT clinical beam: Description and validation. Medical Physics, 2003, 30, 3107-3117.	1.6	18
53	The dosimetric impact of inversely optimized arc radiotherapy plan modulation for real-time dynamic MLC tracking delivery. Medical Physics, 2012, 39, 1588-1594.	1.6	18
54	Motion management during IMAT treatment of mobile lung tumors—A comparison of MLC tracking and gated delivery. Medical Physics, 2014, 41, 101707.	1.6	18

#	Article	IF	CITATIONS
55	Dose painting based on tumor uptake of Cu-ATSM and FDG: a comparative study. Radiation Oncology, 2014, 9, 228.	1.2	18
56	Optimizing the radiation therapy dose prescription for pediatric medulloblastoma: Minimizing the life years lost attributable to failure to control the disease and late complication risk. Acta OncolÅ ³ gica, 2014, 53, 462-470.	0.8	18
57	Doses to head and neck normal tissues for early stage Hodgkin lymphoma after involved node radiotherapy. Radiotherapy and Oncology, 2014, 110, 441-447.	0.3	18
58	Interaction between the biological effects of high- and low-LET radiation dose components in a mixed field exposure. International Journal of Radiation Biology, 2011, 87, 1162-1172.	1.0	17
59	Dose escalation to high-risk sub-volumes based on non-invasive imaging of hypoxia and glycolytic activity in canine solid tumors: a feasibility study. Radiation Oncology, 2013, 8, 262.	1.2	16
60	Impact of beam angle choice on pencil beam scanning breath-hold proton therapy for lung lesions. Acta Oncológica, 2017, 56, 853-859.	0.8	16
61	Daily Adaptive Proton Therapy: Is it Appropriate to Use Analytical Dose Calculations for Plan Adaption?. International Journal of Radiation Oncology Biology Physics, 2020, 107, 747-755.	0.4	16
62	Automated analysis of images acquired with electronic portal imaging device during delivery of quality assurance plans for inversely optimized arc therapy. Radiotherapy and Oncology, 2010, 94, 195-198.	0.3	15
63	Reference dosimetry at the neutron capture therapy facility at Studsvik. Medical Physics, 2003, 30, 1569-1579.	1.6	13
64	Long term safety and visibility of a novel liquid fiducial marker for use in image guided radiotherapy of non-small cell lung cancer. Clinical and Translational Radiation Oncology, 2018, 13, 24-28.	0.9	13
65	Gadolinium neutron capture brachytherapy (GdNCB), a new treatment method for intravascular brachytherapy. Medical Physics, 2005, 33, 46-51.	1.6	12
66	Prompt gamma tomography during BNCT—a feasibility study. Journal of Instrumentation, 2006, 1, P05003-P05003.	0.5	11
67	Modelling of an Orthovoltage X-ray Therapy Unit with the EGSnrc Monte Carlo Package. Journal of Physics: Conference Series, 2007, 74, 021009.	0.3	11
68	A treatment planning study of the potential of geometrical tracking for intensity modulated proton therapy of lung cancer. Acta Oncolųgica, 2010, 49, 1141-1148.	0.8	11
69	Dosimetric benefit of DMLC tracking for conventional and sub-volume boosted prostate intensity-modulated arc radiotherapy. Physics in Medicine and Biology, 2013, 58, 2349-2361.	1.6	11
70	Quality assurance of patient dosimetry in boron neutron capture therapy. Acta Oncológica, 2004, 43, 404-411.	0.8	10
71	Modeling positioning uncertainties of prostate cancer external beam radiation therapy using pre-treatment data. Radiotherapy and Oncology, 2014, 110, 251-255.	0.3	10
72	Volumetric modulated arc therapy dose prediction and deliverable treatment plan generation for prostate cancer patients using a densely connected deep learning model. Physics and Imaging in Radiation Oncology, 2021, 19, 112-119.	1.2	10

#	Article	IF	CITATIONS
73	Experience from long-term monitoring of RAKR ratios in 192Ir brachytherapy. Radiotherapy and Oncology, 2008, 89, 217-221.	0.3	9
74	Percutaneously implanted markers in peripheral lung tumours: Report of complications. Acta Oncológica, 2013, 52, 1225-1228.	0.8	9
75	The impact of leaf width and plan complexity on DMLC tracking of prostate intensity modulated arc therapy. Medical Physics, 2013, 40, 111717.	1.6	9
76	Simulating intrafraction prostate motion with a random walk model. Advances in Radiation Oncology, 2017, 2, 429-436.	0.6	9
77	Image-guided radiotherapy reduces the risk of under-dosing high-risk prostate cancer extra-capsular disease and improves biochemical control. Radiation Oncology, 2018, 13, 64.	1.2	9
78	Influence of volumetric modulated arc therapy and FET-PET scanning on treatment outcomes for glioblastoma patients. Radiotherapy and Oncology, 2019, 130, 149-155.	0.3	9
79	Fast intra-fractional image-guidance with 6D positioning correction reduces delivery uncertainty for stereotactic radiosurgery and radiotherapy. Journal of Radiosurgery and SBRT, 2016, 4, 15-20.	0.2	9
80	Multimodal soft tissue markers for bridging high-resolution diagnostic imaging with therapeutic intervention. Science Advances, 2020, 6, eabb5353.	4.7	8
81	The dosimetric effect of residual breath-hold motion in pencil beam scanned proton therapy – An experimental study. Radiotherapy and Oncology, 2019, 134, 135-142.	0.3	7
82	Tumor-tracking radiotherapy of moving targets; verification using 3D polymer gel, 2D ion-chamber array and biplanar diode array. Journal of Physics: Conference Series, 2010, 250, 012051.	0.3	6
83	Prospective assessment of urinary, gastrointestinal and sexual symptoms before, during and after image-guided volumetric modulated arc therapy for prostate cancer. Scandinavian Journal of Urology, 2015, 49, 58-69.	0.6	6
84	Injectable silver nanosensors: in vivo dosimetry for external beam radiotherapy using positron emission tomography. Nanoscale, 2016, 8, 11002-11011.	2.8	6
85	¹⁸ Fâ€ <scp>FDG PET</scp> / <scp>CT</scp> for planning external beam radiotherapy alters therapy in 11% of 581 patients. Clinical Physiology and Functional Imaging, 2018, 38, 278-284.	0.5	6
86	Modeling Freedom From Progression for Standard-Risk Medulloblastoma: A Mathematical Tumor Control Model With Multiple Modes of Failure. International Journal of Radiation Oncology Biology Physics, 2013, 87, 422-429.	0.4	5
87	Diabetes increases the risk of serious adverse events after re-irradiation of the spine. Radiotherapy and Oncology, 2019, 136, 130-135.	0.3	5
88	Stereotactic radiosurgery versus decompressive surgery followed by postoperative radiotherapy for metastatic spinal cord compression (STEREOCORD): Study protocol of a randomized non-inferiority trial. Journal of Radiosurgery and SBRT, 2016, 4, S1-S9.	0.2	5
89	Use of PET/CT instead of CT-only when planning for radiation therapy does not notably increase life years lost in children being treated for cancer. Pediatric Radiology, 2015, 45, 570-581.	1.1	4
90	"Abscopal―Effect of Radiation Therapy Combined with Immune-Therapy Using IFN-γ Gene Transfected Syngeneic Tumor Cells, in Rats with Bilateral Implanted N29 Tumors. ISRN Immunology, 2011, 2011, 1-13.	0.7	4

#	Article	IF	CITATIONS
91	Automatic FDG-PET-based tumor and metastatic lymph node segmentation in cervical cancer. Proceedings of SPIE, 2014, , .	0.8	3
92	Prospective assessment of the quality of life before, during and after image guided intensity modulated radiotherapy for prostate cancer. Radiation Oncology, 2016, 11, 117.	1.2	3
93	Retrospective estimation of heart and lung doses in pediatric patients treated with spinal irradiation. Radiotherapy and Oncology, 2018, 128, 209-213.	0.3	3
94	NIMG-34THE PROGNOSTIC VALUE OF POSTOPERATIVE O-(2-18F-FLUOROETHYL)-L-TYROSINE POSITRON EMISSION TOMOGRAPHY IN NEWLY DIAGNOSED GLIOBLASTOMA. Neuro-Oncology, 2015, 17, v161.2-v161.	0.6	2
95	A generative model for segmentation of tumor and organs-at-risk for radiation therapy planning of glioblastoma patients. Proceedings of SPIE, 2016, , .	0.8	2
96	Cerebral infarction after fractionated stereotactic radiation therapy of benign anterior skull base tumors. Clinical and Translational Radiation Oncology, 2019, 15, 93-98.	0.9	2
97	Premature Termination of a Randomized Controlled Trial on Imageâ€Guided Stereotactic Body Radiotherapy of Metastatic Spinal Cord Compression. Oncologist, 2020, 25, 210.	1.9	2
98	Residual positioning errors and uncertainties for pediatric craniospinal irradiation and the impact of image guidance. Radiation Oncology, 2020, 15, 149.	1.2	2
99	Survival of Rats with N29 Brain Tumours after Irradiation with 5 or 15 Gy and Immunization with IFN-gamma Secreting Tumour Cells. , 2008, , .		1
100	The Impact of Different PTV Margins in VMAT and IMPT for Adolescents With Nasopharyngeal Carcinoma. International Journal of Radiation Oncology Biology Physics, 2014, 90, S732.	0.4	1
101	PO-0780: Benefit of intra-fraction image-guidance for stereotactic radiotherapy and radiosurgery. Radiotherapy and Oncology, 2015, 115, S389.	0.3	1
102	PO-0964: Artefact quantification of liquid and solid fiducial marker in single and dual energy CT with MAR. Radiotherapy and Oncology, 2015, 115, S510.	0.3	1
103	EP-1301: Health related quality of life measurements following re-irradiation of metastatic spinal cord compression. Radiotherapy and Oncology, 2015, 115, S701-S702.	0.3	1
104	The Interplay Effect in Gated and Non-gated IMRT for Breast Cancer: Impact of Breathing Motion and Gating Parameters. International Journal of Radiation Oncology Biology Physics, 2010, 78, S719.	0.4	0
105	Estimating Life Years Lost to Quantify the Potential Benefit for Pediatric Patients of Advanced Photon or Proton Radiotherapy. International Journal of Radiation Oncology Biology Physics, 2011, 81, S665.	0.4	0
106	Contour Propagation With Riemannian Elasticity Regularization. International Journal of Radiation Oncology Biology Physics, 2011, 81, S807.	0.4	0
107	Comparison of Cardiac Doses after Involved Node Radiotherapy and Mantle Field Treatment for Hodgkin Lymphoma. International Journal of Radiation Oncology Biology Physics, 2011, 81, S19.	0.4	0
108	A Dosimetric Comparison of MLC Tracking and Gated Delivery of Arc Therapy to a Moving Target. International Journal of Radiation Oncology Biology Physics, 2012, 84, S733.	0.4	0

#	Article	IF	CITATIONS
109	The Clinical Commissioning of Beams for Neutron Capture Therapy. , 2012, , 259-275.		0
110	Results of PET/CT Planned IMRT and Concomitant Boost to Lymph Node Metastasis in Patients With Cervical Cancer. International Journal of Radiation Oncology Biology Physics, 2012, 84, S440.	0.4	0
111	PD-0416: Robust feature auto-segmentation of head and neck cancer. Radiotherapy and Oncology, 2013, 106, S160.	0.3	0
112	Prospective Assessment of Urinary, Gastrointestinal, and Sexual Symptoms Before, During, and After Image-Guided Intensity Modulated Radiation Therapy for Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2014, 90, S405-S406.	0.4	0
113	PET/CT-guided treatment planning for paediatric cancer patients: a simulation study of proton and conventional photon therapy. British Journal of Radiology, 2015, 88, 20140586.	1.0	0
114	RA-07FEASIBILITY OF EARLY POSTOPERATIVE18F-FET PET/MRI AFTER SURGERY FOR BRAIN TUMOR IN PEDIATRIC PATIENTS. Neuro-Oncology, 2016, 18, iii166.2-iii166.	0.6	0
115	OC-0301: Target position uncertainty during visually guided breathhold radiotherapy in locally advanced NSCLC. Radiotherapy and Oncology, 2017, 123, S155-S156.	0.3	0
116	EP-1462: The impact on VMAT optimization using Type C vs B algorithms for patients with temporary gas pockets. Radiotherapy and Oncology, 2017, 123, S780-S781.	0.3	0
117	PO-0642: Influence of Introduction of VMAT and FET-PET on Treatment Outcomes for Glioblastoma Patients. Radiotherapy and Oncology, 2017, 123, S336.	0.3	0
118	RTHP-28. PREDICTION OF RECURRENCE PATTERNS USING DIFFUSION DRIVEN GROWTH MODELING FOR GLIOBLASTOMA. Neuro-Oncology, 2017, 19, vi224-vi224.	0.6	0
119	PO-0946: Breath-hold motion effect in pencil beam scanned proton therapy for lung cancer – experimental study. Radiotherapy and Oncology, 2018, 127, S515-S516.	0.3	0
120	EP-1812: Proton pencil beam scanning with motion emulated as spot shifts: dose reconstruction for lung cancer. Radiotherapy and Oncology, 2018, 127, S974-S975.	0.3	0
121	EP-2114: Prediction of recurrence patterns using diffusion driven growth modelling for glioblastoma. Radiotherapy and Oncology, 2018, 127, S1162-S1163.	0.3	0
122	PO-0990 Positioning uncertainties for pediatric craniospinal irradiation and the impact of image guidance. Radiotherapy and Oncology, 2019, 133, S544-S545.	0.3	0
123	SU-F-T-123: The Simulated Effect of the Breath-Hold Reproducibility Treating Locally-Advanced Lung Cancer with Pencil Beam Scanned Proton Therapy. Medical Physics, 2016, 43, 3490-3490.	1.6	0